Please assess the completion status of the following clinical trial:

Trial Title: Albumin in Acute Ischemic Stroke Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Acute ischemic stroke~* NIH stroke scale score \> 5~* Age \>= 18 and \<= 83~* ALB or placebo can be administered within 5 hours of symptom onset~* ALB or placebo can be administered within 60 minutes of Tissue Plasminogen Activator (tPA) administration in the thrombolysis group~* Signed informed consent~Exclusion Criteria:~* Episode/exacerbation of congestive heart failure (CHF) from any cause in the last 6 months. An episode of congestive heart failure is any heart failure that required a change in medication, diet or hospitalization.~* Known valvular heart disease with CHF in the last 6 months.~* Severe aortic stenosis or mitral stenosis.~* Cardiac surgery involving thoracotomy (e.g., coronary artery bypass graft (CABG), valve replacement surgery) in the last 6 months.~* Acute myocardial infarction in the last 6 months.~* Signs or symptoms of acute myocardial infarction, including ECG findings, on admission.~* Baseline elevated serum troponin level on admission (\>0.1 mcg/L)~* Suspicion of aortic dissection on admission.~* Acute arrhythmia (including any tachycardia - or bradycardia) with hemodynamic instability.~* Findings on physical examination of any of the following: (1) jugular venous distention (JVP \> 4 cm above the sternal angle); (2) 3rd heart sound; (3) resting tachycardia (heart rate \> 100/min) attributable to congestive heart failure; (4) abnormal hepatojugular reflux; (5) lower extremity pitting edema attributable to congestive heart failure; and/or (6) definite chest x-ray evidence of pulmonary edema.~* Current acute or chronic lung disease requiring supplemental chronic or intermittent oxygen therapy.~* Historical Modified Rankin Score (mRS) ≥2. Patients who live in a nursing home or who are not fully independent for activities of daily living immediately prior to the stroke are not eligible for the trial.~* In-patient stroke. I.e., patients with a stroke occurring as a complication of hospitalization for another condition, or as a complication of a procedure.~* Planned acute use of intra-arterial (IA) tPA or acute endovascular intervention (e.g., stenting, angioplasty, thrombus retrieval device use) must conform to the following criteria: (1) begin within 5 hours of symptom onset, and (2) finish within 7 hours of symptom-onset.~* Fever, defined as core body temperature \> 37.5° C (99.5°F).~* Serum creatinine \> 2.0 mg/dL or 180 µmol/L.~* Profound dehydration.~* Evidence of intracranial hemorrhage (intracerebral hematoma (ICH), subarachnoid hemorrhage (SAH), epidural hemorrhage, acute or chronic subdural hematoma (SDH)) on the baseline CT or MRI scan.~* History of allergy to albumin.~* History of latex rubber allergy.~* Severe chronic anemia with Hgb \< 7.5 g/dL~* Pregnancy, breastfeeding or positive pregnancy test. (Women of childbearing age must have a negative pregnancy test prior to ALB administration.)~* Concurrent participation in any other therapeutic clinical trial.~* Evidence of any other major life-threatening or serious medical condition that would prevent completion of 3-month follow-up, impair the assessment of outcome, or in which ALB therapy would be contraindicated or might cause harm to the subject.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 83 Years
- Healthy Volunteers: f

Study Arms:
- Albumin (ALB) (Type: ACTIVE_COMPARATOR): Albumin (human albumin, 25% solution, 2.0 g/kg), infused intravenously over a period of 2 hours
- Saline (Type: PLACEBO_COMPARATOR): Saline (isotonic solution), 8 ml/kg, infused intravenously over a 2-hour period

Based on this trial design, predict the completion outcome and termination type (if applicable).